VBiolabs

VBiolabs is very experienced in antibody humanisation. The major disadvantage of using murine monoclonal antibodies as therapeutic drugs is that it leads to human anti-murine antibody (HAMA) response. Our antibody humanisation strategies have been developed to overcome this technical hurdle while maintaining the specific affinity of an antibody toward its original antigen.

Domain switch

Variable domains of murine antibody can be recombined with human antibody constant domains to produce a chimeric antibody. The chimeric antibody enables researchers to convert a murine monoclonal antibody into one that has some features of a human antibody but still retains its original binding specificity. These humanised murine antibodies enable multiple dosing of therapy and increased half-life of each dose.

CDR grafting

A functional humanised antibody can be created by grafting the antigen binding complementarity determining regions (CDRs) from variable domains of rodent antibodies onto human variable domains. We used a computer programme to analyse the amino acid sequence of the mouse variable regions to identify the residues that are most critical in antigen-binding.

Guided chain selection

We have a chain selection strategy by which humanised antibodies with different sequences, structure and epitopes could be generated, indicating potential alternative clinical treatments. This strategy allows light chain (and then heavy chain), of a rodent antibody to be replaced by a human light chain (and then heavy chain) antibody library followed by two successive immuno-binding selections. After two round of screening, fully humanised antibodies can be generated. This guided chain selection strategy results in high affinity of humanised antibodies through artificial evolution procedures.